Regeneron Pharmaceuticals Inc (REGN) — Capital Reinvestment Ratio
Regeneron Pharmaceuticals Inc (REGN) has a Capital Reinvestment Ratio of 0.21x as of March 2026, meaning it reinvests 0% of its operating cash flow ($1.08 Billion) in capital expenditures ($230.60 Million). See Regeneron Pharmaceuticals Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Regeneron Pharmaceuticals Inc Capital Reinvestment Ratio (2006–2025)
This chart tracks Regeneron Pharmaceuticals Inc's Capital Reinvestment Ratio across 16 annual periods.
Annual Capital Reinvestment Ratio for Regeneron Pharmaceuticals Inc (2006–2025)
Year-by-year Capital Reinvestment Ratio for Regeneron Pharmaceuticals Inc from 2006 to 2025. For live market cap and broader valuation context, see market value of Regeneron Pharmaceuticals Inc.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.18x | $4.98 Billion | $898.40 Million | ▲ +5.5% |
| 2024 | 0.17x | $4.42 Billion | $755.90 Million | ▼ -15.2% |
| 2023 | 0.20x | $4.59 Billion | $926.40 Million | ▲ +71.4% |
| 2022 | 0.12x | $5.01 Billion | $590.10 Million | ▲ +51.0% |
| 2021 | 0.08x | $7.08 Billion | $551.90 Million | ▼ -66.8% |
| 2020 | 0.23x | $2.62 Billion | $614.60 Million | ▲ +32.8% |
| 2019 | 0.18x | $2.43 Billion | $429.60 Million | ▲ +1.3% |
| 2018 | 0.17x | $2.20 Billion | $383.10 Million | ▼ -16.3% |
| 2017 | 0.21x | $1.31 Billion | $272.60 Million | ▼ -39.5% |
| 2016 | 0.34x | $1.49 Billion | $511.90 Million | ▼ -32.4% |
| 2015 | 0.51x | $1.33 Billion | $677.93 Million | ▲ +15.1% |
| 2014 | 0.44x | $752.43 Million | $333.01 Million | ▲ +66.6% |
| 2013 | 0.27x | $588.60 Million | $156.32 Million | ▼ -74.3% |
| 2010 | 1.03x | $96.34 Million | $99.69 Million | ▲ +53.5% |
| 2007 | 0.67x | $27.37 Million | $18.45 Million | ▲ +453.2% |
| 2006 | 0.12x | $23.07 Million | $2.81 Million | — |